Publications

2019

Goswami, P., et al., Minimal Clinically Important Difference and Responsiveness for HM-PRO in Patients with Hematological Malignancies. Accepted in Haematologica. [Abstract EHA- PF721].

2018

Goswami Pet al. Assessment of measurement equivalence of the paper-based and electronic version of a newly developed haematology specific patient-reported outcome measure, HM-PRO. Accepted for PROM conference. [Abstract 63}.

Goswami, P., et al., Translating the Science of Patient Reported Outcomes into Practice: Meaningfulness of HM-PRO Scores in Patients with Hematological Malignancies. Blood, 2018. 132(Suppl 1): p. 4860-4860.

Oliva, E.N., et al., Impact of AML on Patients’ Lives: The Value of HM-PRO Measurements. Blood, 2018. 132(Suppl 1): p. 5900-5900.

Goswami P et al, Comparison of the paper-based and electronic version of a new patient-reported Outcome measure in haematological malignancy for use in clinical practice, HM-PRO: an Equivalence study. Accepted in Haematologica. [Abstract EHA-3118].

Goswami, P., et al., Responsiveness and the Minimal Clinically Important Difference for HM-PRO in Patients with Hematological Malignancies. Blood, 2018. 132(Suppl 1): p. 2294-2294.

2017

Goswami P et al, Development of a novel patient reported outcome measure for patients with haematological malignancy: a qualitative study Health and Quality of Life Outcomes 2017, 15(Suppl 1) [Abstract A59].

Goswami P et al, Development of a new haematological malignant patient-reported outcome measure for use in clinical practice: HM-PRO. Haematologica June 2017 102: 1-882. [Abstract E1476].

Goswami, P et al (2017). HM-PRO: A Novel Patient-Reported Outcome Measure in Hematological Malignancy for Use in Clinical Practice. Blood, 130 (Suppl 1), 2176.

2016

Goswami, P., Salek, S., Fielding, A. K., Kell, J., Al-Ismail, S., Oliva, E., Ionova, T., Else, R., Karakantza, M., Jennings, D., & Waldmann, A. (2016).Development of a Novel Patient-Reported Outcome Measure in Haematological Malignancy for Use in Routine Clinical Practice: Item Generation. Blood, 128(22), 5985

Goswami, P., Salek, S., Fielding, A., Jonathan, K., Else, R., Oliva, E., Lonova, T. (2016). ‘The Impact of Haematological Malignancy on Patients’ Health-related quality of life and symptoms: A Qualitative study’. Haematologica 101: 1-881 [Abstract E1447].

2020

Quality-of-life issues and symptoms reported by patients living with haematological malignancy: a qualitative study. Pushpendra Goswami, Esther N. Oliva, Tatyana Ionova, Roger Else, Jonathan Kell, Adele K. Fielding, Daniel M. Jennings, Marina Karakantza, Saad Al-Ismail, Graham P. Collins, Stewart McConnell, Catherine Langton and Sam Salek (2020). Ther Adv Hematol, Vol. 11:1–14. doi:/10.1177/2040620720955002

Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity. Goswami P, Oliva EN, Ionova T, Else R, Kell J, Fielding AK, Jennings DM, Karakantza M, Al-Ismail S, Collins GP, McConnell S, Langton C and Salek S (2020). Front. Pharmacol. 11:209. doi:10.3389/fphar.2020.00209

Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome – Measure: HM-PRO. Goswami P, Oliva EN, Ionova T, Else R, Kell J, Fielding AK, Jennings DM, Karakantza M, Al-Ismail S, Collins GP, McConnell S, Langton C, Al- Obaidi MJ, Oblak M and Salek S (2020). Front. Pharmacol. 11:571066. doi: 10.3389/fphar.2020.571066

Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study. Goswami P, Oliva EN, Ionova T, Else R, Kell J, Fielding AK, Jennings DM, Karakantza M, Al-Ismail S, Collins GP, McConnell S, Langton C, Al-Obaidi MJ, Oblak M and Salek S (2020). Front. Pharmacol. 11:1308. doi: 10.3389/fphar.2020.01308

2019

Haematological malignancy: Are we measuring what is important to patients? A systematic review of quality‐of‐life instruments. Pushpendra Goswami, Yasmin Khatib, Sam Salek (2019). Eur J Haematol.102:279–311. doi: 10.1111/ejh.13203

Paper and electronic versions of HM-PRO, a novel patient-reported outcome measure for hematology: an equivalence study. Pushpendra Goswami, Esther N Oliva, Tatyana Ionova , Roger Else, Jonathan Kell, Adele K Fielding, Daniel M Jennings, Marina Karakantza, Saad Al-Ismail, Jack Lyness , Graham P Collins , Stewart McConnell, Catherine Langton, Magda Jabbar Al-Obaidi, Metod Oblak & Sam Salek (2019). J.Comp.Eff.Res. doi10.2217/cer-2018-0108.

2020

Translating patient-reported outcome scores into practice: Interpretability of the HM-PRO. Pushpendra Goswami, Tatyana Ionova, Esther N Oliva, Roger Else, Jonathan Kell, Adele K Fielding, Daniel M Jennings, Marina Karakantza, Saad Al-Ismail, Graham P Collins, Stewart McConnell, Catherine Langton, Magda Jabbar Al-Obaidi, Metod Oblak & Sam Salek.

Responsiveness of the HM-PRO. Pushpendra Goswami, Tatyana Ionova, Esther N Oliva, Roger Else, Jonathan Kell, Adele K Fielding, Daniel M Jennings, Marina Karakantza, Saad Al-Ismail, Graham P Collins, Stewart McConnell, Catherine Langton, Magda Jabbar Al-Obaidi, Metod Oblak & Sam Salek.